Intensity Therapeutics, Inc.
NASDAQ: INTS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lewis H. Bender
- Employees
- 5
- Headquarters
- Westport, United States
- IPO year
- 2023
- Market cap
- $7.7M
- Website
- https://www.intensitytherapeutics.com
Loading INTS…
Loading profile data…Frequently asked questions about INTS
What does Intensity Therapeutics, Inc. (INTS) do?
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range...
Where does INTS trade?
Intensity Therapeutics, Inc. (INTS) trades on the NASDAQ Capital Market.
What sector is INTS in?
Intensity Therapeutics, Inc. (INTS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Intensity Therapeutics, Inc.?
Lewis H. Bender is the chief executive officer of Intensity Therapeutics, Inc. (INTS).
Where is Intensity Therapeutics, Inc. headquartered?
Intensity Therapeutics, Inc. is headquartered in United States.
Does INTS pay a dividend?
Intensity Therapeutics, Inc. (INTS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INTS go public?
Intensity Therapeutics, Inc. (INTS) completed its initial public offering in 2023.